These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 18589141)

  • 1. Heparin-induced thrombocytopenia after liver transplantation.
    Kaneko J; Sugawara Y; Tamura S; Togashi J; Matsui Y; Makuuchi M
    Transplant Proc; 2008 Jun; 40(5):1518-21. PubMed ID: 18589141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II].
    Ganzer D; Gutezeit A; Mayer G; Greinacher A; Eichler P
    Z Orthop Ihre Grenzgeb; 1997; 135(6):543-9. PubMed ID: 9499523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?
    Lubenow N; Hinz P; Ekkernkamp A; Greinacher A
    Eur J Haematol; 2007 Sep; 79(3):187-90. PubMed ID: 17655709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of heparin-induced thrombocytopenia].
    Wang JH; Wang CY; Xie R; Che DH; Jia RC; Ju W; Miao MJ; Wang H; Jiang Y; Tong DX
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):115-7. PubMed ID: 21429379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis.
    Randi ML; Tezza F; Scapin M; Duner E; Scarparo P; Scandellari R; Fabris F
    Acta Haematol; 2010; 123(3):140-5. PubMed ID: 20134155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital.
    Ban-Hoefen M; Francis C
    Thromb Res; 2009 Jun; 124(2):189-92. PubMed ID: 19195684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.
    Warkentin TE; Roberts RS; Hirsh J; Kelton JG
    Arch Intern Med; 2003 Nov; 163(20):2518-24. PubMed ID: 14609790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.
    Walenga JM; Jeske WP; Prechel MM; Bacher P; Bakhos M
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():69-80. PubMed ID: 15085468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
    Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
    Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes.
    Baroletti S; Piovella C; Fanikos J; Labreche M; Lin J; Goldhaber SZ
    Thromb Haemost; 2008 Dec; 100(6):1130-5. PubMed ID: 19132240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients.
    Schroder JN; Daneshmand MA; Villamizar NR; Petersen RP; Blue LJ; Welsby IJ; Lodge AJ; Ortel TL; Rogers JG; Milano CA
    Ann Thorac Surg; 2007 Sep; 84(3):841-5; discussion 845-6. PubMed ID: 17720387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
    Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
    Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
    Junqueira DR; Perini E; Penholati RR; Carvalho MG
    Cochrane Database Syst Rev; 2012 Sep; (9):CD007557. PubMed ID: 22972111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
    ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
    Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population.
    Mullen MP; Wessel DL; Thomas KC; Gauvreau K; Neufeld EJ; McGowan FX; Dinardo JA
    Anesth Analg; 2008 Aug; 107(2):371-8. PubMed ID: 18633010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases.
    Refaai MA; Van Cott EM; Laposata M
    Am J Clin Pathol; 2003 Apr; 119(4):497-504. PubMed ID: 12710122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Heparin induced thrombocytopenia type II after the use of low-molecular weight heparin. Case report and review of the literature].
    Franke J; Schaeper O; Kayser R; Mahlfeld K
    Unfallchirurg; 2003 Jan; 106(1):77-81. PubMed ID: 12552397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of liver transplantation in a patient with a history of heparin-induced thrombocytopenia.
    Fretschner R; Dietrich K; Unertl K; Greinacher A
    Transpl Int; 2005 Jun; 18(6):664-7. PubMed ID: 15910290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-induced thrombocytopenia: recent experience in a large teaching hospital.
    Sturtevant JM; Pillans PI; Mackenzie F; Gibbs HH
    Intern Med J; 2006 Jul; 36(7):431-6. PubMed ID: 16780449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.